文献速递心境障碍

MDMA辅助治疗重性抑郁障碍的原理验证研究

MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.
PubMed 文献 · Br J Psychiatry · 2025-07-11

主要终点MADRS从基线29.6显著下降19.3分(P<0.001),SDS功能损害显著改善11.7分(P=0.001),无特殊关注或严重不良事件,提示安全可行且具初步疗效。

要点

  • SDS功能损害较基线显著改善11.7分,未报告特殊关注或严重不良事件。
  • 结果为开放标签原理验证,需随机对照研究确认疗效。

核心结论

  • MDMA辅助治疗重性抑郁障碍达到安全性与可行性主要目标,并显示初步疗效信号。

研究设计与样本

  • 患者间隔1个月接受2次MDMA sessions,并在session前后及期间接受心理治疗。

主要发现

  • 基线MADRS为29.6(s.d. 4.9),治疗后较基线平均下降19.3分(s.e. 2.4,CI -14.8至-23.8,P<0.001)。
  • SDS较基线平均下降11.7分(s.e. 2.2,CI -7.5至-15.9,P=0.001)。
  • 未出现特殊关注不良事件,也无意外或严重不良事件。

关键数值与推荐

  • 主要结局为MADRS从基线至第2次MDMA session后8周的平均变化。
  • 次要结局为SDS功能损害从基线至第2次MDMA session后8周的平均变化。

临床怎么用

  • 结果支持在严格研究条件下进一步评估MDMA辅助治疗作为MDD治疗选项。
  • 临床决策前需等待随机对照设计研究确认疗效。

局限性

  • 作者指出需随机设计研究确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic stress disorder, but has not been investigated for a primary diagnosis of major depressive disorder (MDD). AIM: We aimed to explore the proof of principle and safety as a first study with MDMA-AT for MDD, and to provide preliminary efficacy data. METHOD: Twelve participants (7 women, 5 men) with moderate to severe MDD received MDMA in 2 open-label sessions 1 month apart, along with psychotherapy before, during and after the MDMA sessions, between January 2023 and May 2024. The primary outcome measure was mean change in Montgomery-Asberg Depression Rating Scale (MADRS), and the secondary outcome measure was mean change in functional impairment as measured with the Sheehan Disability Scale (SDS), both from baseline to 8 weeks following the second MDMA session. We used descriptive statistics and the two-tailed Wilcoxon signed-rank test to compare baseline and outcome scores. Repeated measures were analysed by a mixed-effects model. RESULTS: Baseline MADRS was 29.6 (s.d. 4.9). Feasibility was demonstrated with sufficient recruitment and retention. MADRS scores were significantly reduced post treatment compared with baseline (mean difference -19.3, s.e. 2.4, CI -14.8 to -23.8, P < 0.001). SDS scores significantly decreased from baseline (mean difference -11.7, s.e. 2.2, CI -7.5 to -15.9, P = 0.001). There were no adverse events of special interest, and no unexpected or serious adverse events. CONCLUSION: The study met the primary objectives of safety and feasibility, and provided indications of efficacy for MDMA-AT for MDD. Further studies with a randomised design are required to confirm these findings. TRIAL REGISTRATION: EudraCT no. 2021-000805-26.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kvam TM, Goksøyr IW, Rog J, et al. MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study. Br J Psychiatry. 2025. PMID: 40641116. doi:10.1192/bjp.2025.10320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。